Capecitabine 500mg Tablets (Camber USA) Now Available Under TGA Section 19A

Dear Healthcare Professional,

Shortage of XELABINE (Capecitabine 500 mg) – AUST R: 213045

Pro Pharmaceuticals Group acknowledges the ongoing shortage of XELABINE capecitabine 500 mg film-coated tablets (AUST R: 213045), a critical chemotherapy medicine used in the treatment of colorectal, breast, and gastric cancers. The shortage has arisen due to an unexpected surge in demand, affecting timely access for patients across Australia.

To support continuity of care, Pro Pharmaceuticals Group has secured supply of an alternative product – Capecitabine Tablets USP 500 mg (Camber Pharmaceuticals, USA).

This product is not registered in Australia but has been approved for supply under TGA Section 19A exemption until 31 July 2025, in accordance with the Therapeutic Goods Act 1989.

We encourage hospital pharmacies and oncology services to share this information with relevant clinical and procurement teams.

📧 For orders or further enquiries, please email: orders@propg.com.au

🌐 Or visit: www.propg.com.au